147 related articles for article (PubMed ID: 6105670)
1. Tardive dyskinesia: a biological appraoch.
Barbaccia ML; Trabucchi M
Prog Clin Biol Res; 1980; 39():181-93. PubMed ID: 6105670
[No Abstract] [Full Text] [Related]
2. Tardive dyskinesia: pathophysiology and animal models.
Casey DE
J Clin Psychiatry; 2000; 61 Suppl 4():5-9. PubMed ID: 10739324
[TBL] [Abstract][Full Text] [Related]
3. [What is the connection between Parkinson disease and tardive dyskinesia?].
Gunne LM; Andrén PE
Lakartidningen; 1994 Aug; 91(34):2953-5. PubMed ID: 7990538
[No Abstract] [Full Text] [Related]
4. [Tardive dyskinesias. Epidemiology and physiopathology].
Gerlach J
Ugeskr Laeger; 1987 Jun; 149(25):1678-81. PubMed ID: 2885954
[No Abstract] [Full Text] [Related]
5. [Neuroleptic parkinsonism and tardive dyskinesia and methods of pharmacologically correcting these pathologic conditions (review)].
Arushanian EB
Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(2):269-77. PubMed ID: 2858951
[No Abstract] [Full Text] [Related]
6. The pathophysiologic basis of tardive dyskinesia.
Baldessarini RJ
Psychopharmacol Bull; 1978 Oct; 14(4):79-81. PubMed ID: 30114
[No Abstract] [Full Text] [Related]
7. Tardive dyskinesia: a role for the endogenous opioid system.
Sandyk R
Med Hypotheses; 1986 Jan; 19(1):71-4. PubMed ID: 2871480
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiologic basis of tardive dyskinesia.
Baldessarini RJ; Tarsy D
Adv Biochem Psychopharmacol; 1980; 24():451-5. PubMed ID: 6105793
[No Abstract] [Full Text] [Related]
9. Biochemical methods for predicting the occurrence of tardive dyskinesia.
Bürki HR
Commun Psychopharmacol; 1979; 3(1):7-15. PubMed ID: 38033
[No Abstract] [Full Text] [Related]
10. Adaptive changes in brain dopamine function as a result of neuroleptic treatment.
Jenner P; Marsden CD
Adv Neurol; 1988; 49():417-31. PubMed ID: 2894127
[No Abstract] [Full Text] [Related]
11. ECT and tardive dyskinesia.
Lerer B
J Clin Psychiatry; 1984 Apr; 45(4):188. PubMed ID: 6715296
[No Abstract] [Full Text] [Related]
12. Pharmacologic studies of tardive dyskinesia.
Chase TN; Tamminga CA
Adv Biochem Psychopharmacol; 1980; 24():457-61. PubMed ID: 7405673
[No Abstract] [Full Text] [Related]
13. [Physiopathology and curative treatment of tardive dyskinesia].
Wolf MA; Gautier J
Encephale; 1987; 13(5):301-8. PubMed ID: 2892663
[TBL] [Abstract][Full Text] [Related]
14. Animal models of tardive dyskinesia--a review.
Kulkarni SK; Naidu PS
Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
[TBL] [Abstract][Full Text] [Related]
15. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
[TBL] [Abstract][Full Text] [Related]
16. Dopamine-sensitive adenylate cyclase and receptor binding activities after acute and chronic neuroleptic drug treatment.
Clement-Cormier Y
Adv Biochem Psychopharmacol; 1980; 24():103-11. PubMed ID: 6105768
[No Abstract] [Full Text] [Related]
17. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs.
Baldessarini RJ; Tarsy D
Annu Rev Neurosci; 1980; 3():23-41. PubMed ID: 6106450
[No Abstract] [Full Text] [Related]
18. Use of dopamine receptor agonists to reduce dopamine receptor number as treatment for tardive dyskinesia.
Alpert M; Friedhoff AJ; Diamond F
Adv Neurol; 1983; 37():253-8. PubMed ID: 6134444
[No Abstract] [Full Text] [Related]
19. [Neuroleptic-induced tardive dyskinesia: recent pathophysiological data, therapeutic trials (author's transl)].
Gaillard-Sizaret C; Gaillard P
Therapie; 1979; 34(5):555-74. PubMed ID: 44767
[No Abstract] [Full Text] [Related]
20. Dopamine receptor function and spontaneous orofacial dyskinesia in rats during 6-month neuroleptic treatments.
Waddington JL; Cross AJ; Gamble SJ; Bourne RC
Adv Biochem Psychopharmacol; 1983; 37():299-308. PubMed ID: 6138952
[No Abstract] [Full Text] [Related]
[Next] [New Search]
